Pradžia › Kartotinė mieloma › North Carolina › Durham
Kartotinė mieloma klinikiniai tyrimai Durham, NC
37 tyrimai dėl Kartotinė mieloma ieško dalyvių vietose Durham ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Renkami dalyviai3 fazė
- Research Site, Chapel Hill · už 10 mylių
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai3 fazė
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Renkami dalyviai2 fazė
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai3 fazė
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · už 10 mylių
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Renkami dalyviai3 fazė
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Renkami dalyviai2/3 fazė
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · už 10 mylių
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Renkami dalyviai2 fazė
- Lineberger Comprehensive Cancer Center, Chapel Hill · už 10 mylių
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Renkami dalyviai3 fazė
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai2 fazė
- University of North Carolina Medical Center, Chapel Hill · už 10 mylių
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Renkami dalyviai1/2 fazė
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · už 10 mylių
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Renkami dalyviai2 fazė
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- University of North Carolina Hospitals at Hillsborough, Hillsborough · už 13 mylių
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Renkami dalyviai1/2 fazė
- GSK Investigational Site, Chapel Hill · už 10 mylių
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Renkami dalyviai1/2 fazė
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Renkami dalyviai3 fazė
- Research Site, Durham
- Research Site, Chapel Hill · už 10 mylių
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Renkami dalyviai
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · už 10 mylių
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Renkami dalyviai1 fazė
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Renkami dalyviai2 fazė
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · už 10 mylių
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Renkami dalyviai1/2 fazė
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · už 10 mylių
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Renkami dalyviai1/2 fazė
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- University of North Carolina /ID# 251203, Chapel Hill · už 10 mylių
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Renkami dalyviai1 fazė
- University of North Carolina at Chapel Hill, Chapel Hill · už 10 mylių
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Renkami dalyviai2 fazė
- University of North Carolina (Data Collection Only), Chapel Hill · už 10 mylių
Registry of Older Patients With Cancer
Renkami dalyviaiStebimasis tyrimas
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · už 10 mylių
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Renkami dalyviai3 fazė
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Renkami dalyviai2 fazė
- University of North Carolina, Chapel Hill · už 10 mylių
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Renkami dalyviai2 fazė
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · už 10 mylių
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · už 10 mylių
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Renkami dalyviai1/2 fazė
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · už 13 mylių
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Renkami dalyviai1 fazė
- University of North Carolina, Chapel Hill · už 10 mylių
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Renkami dalyviai1 fazė
- University of North Carolina, Chapel Hill · už 10 mylių
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Renkami dalyviai1/2 fazė
- Duke University, Durham
- UNC Hospital, Chapel Hill · už 10 mylių
Registry for Adults With Plasma Cell Disorders (PCD's)
Renkami dalyviaiStebimasis tyrimas
- North Carolina Cancer Hospital, Chapel Hill · už 10 mylių
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Renkami dalyviaiStebimasis tyrimas
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · už 10 mylių
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- Duke University Health System (DUHS), Durham
Kartotinė mieloma tyrimai kituose miestuose
- New York City, NY60 tyrimai
- Boston, MA42 tyrimai
- Atlanta, GA41 tyrimas
- Houston, TX38 tyrimai
- Nashville, TN32 tyrimai
- Denver, CO27 tyrimai
- Rochester, MN24 tyrimai
- St. Louis, MO24 tyrimai
- Columbus, OH24 tyrimai
- Baldwin Park, CA23 tyrimai
- Chicago, IL22 tyrimai
- Seattle, WA22 tyrimai
Kiti tyrimai Durham
- Krūties vėžys63 tyrimai
- Vėžys (visų tipų)58 tyrimai
- Nedidelinių ląstelių plaučių vėžys39 tyrimai
- Metastatinis vėžys33 tyrimai
- Ūmi mieloidinė leukemija33 tyrimai
- Plaučių vėžys32 tyrimai
- Prostatos vėžys32 tyrimai
- Storosios ir tiesiosios žarnos vėžys28 tyrimai
- Lėtinė limfocitinė leukemija27 tyrimai
- Kiaušidžių vėžys27 tyrimai
- Širdies nepakankamumas26 tyrimai
- Kasos vėžys24 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.